Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 2
2011 1
2013 1
2014 1
2017 1
2018 1
2019 2
2020 1
2021 2
2022 1
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.
Harada T, Oizumi S, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, Inoue A, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Harada T, et al. Oncologist. 2013;18(4):439-45. doi: 10.1634/theoncologist.2012-0308. Epub 2013 Feb 26. Oncologist. 2013. PMID: 23442308 Free PMC article. Clinical Trial.
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
Fukumoto SI, Oizumi S, Harada M, Sukoh N, Nakano K, Fuke S, Sakakibara-Konishi J, Takamura K, Ito K, Fujita Y, Nishigaki Y, Harada T, Akie K, Kinoshita I, Amano T, Isobe H, Dosaka-Akita H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Fukumoto SI, et al. Cancer Chemother Pharmacol. 2020 Jul;86(1):117-127. doi: 10.1007/s00280-020-04104-1. Epub 2020 Jun 20. Cancer Chemother Pharmacol. 2020. PMID: 32564128 Clinical Trial.
Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.
Morinaga D, Asahina H, Ito S, Honjo O, Tanaka H, Honda R, Yokouchi H, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group Trial. Morinaga D, et al. Cancer Med. 2023 May;12(10):11525-11541. doi: 10.1002/cam4.5889. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999734 Free PMC article.
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.
Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, Harada T, Harada M, Takamura K, Oizumi S, Kinoshita I, Katsuura Y, Honjo O, Kojima T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Kanazawa K, et al. Cancer Chemother Pharmacol. 2014 Dec;74(6):1149-57. doi: 10.1007/s00280-014-2589-3. Epub 2014 Oct 8. Cancer Chemother Pharmacol. 2014. PMID: 25294632 Clinical Trial.
Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
Akie K, Oizumi S, Ogura S, Shinagawa N, Kikuchi E, Fukumoto S, Harada M, Kinoshita I, Kojima T, Harada T, Fujita Y, Ohsaki Y, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Akie K, et al. Oncology. 2011;81(2):84-90. doi: 10.1159/000331681. Epub 2011 Oct 3. Oncology. 2011. PMID: 21968255 Free article. Clinical Trial.
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H, Oizumi S, Takamura K, Harada T, Harada M, Yokouchi H, Kanazawa K, Fujita Y, Kojima T, Sugaya F, Tanaka H, Honda R, Kikuchi E, Ikari T, Ogi T, Shimizu K, Suzuki M, Konno S, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Asahina H, et al. Lung Cancer. 2019 Dec;138:65-71. doi: 10.1016/j.lungcan.2019.09.020. Epub 2019 Sep 30. Lung Cancer. 2019. PMID: 31654836 Free article. Clinical Trial.
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).
Yamamoto G, Asahina H, Honjo O, Sumi T, Nakamura A, Ito K, Kikuchi H, Hommura F, Honda R, Yokoo K, Fujita Y, Oizumi S, Morita R, Ikezawa Y, Tanaka H, Kimura N, Sasaki T, Sukoh N, Takashina T, Harada T, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group Trial. Yamamoto G, et al. Sci Rep. 2021 Nov 30;11(1):23140. doi: 10.1038/s41598-021-02561-z. Sci Rep. 2021. PMID: 34848786 Free PMC article.
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M, Sakakibara-Konishi J, Kikuchi H, Yokouchi H, Nishihara H, Minemura H, Harada M, Yamazaki S, Akie K, Fujita Y, Takamura K, Kojima T, Harada T, Minami Y, Watanabe N, Oizumi S, Suzuki H, Nishimura M, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group. Furuta M, et al. Oncologist. 2019 Nov;24(11):e1172-e1179. doi: 10.1634/theoncologist.2018-0676. Epub 2019 May 8. Oncologist. 2019. PMID: 31068386 Free PMC article.
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
Asahina H, Oizumi S, Inoue A, Kinoshita I, Ishida T, Fujita Y, Sukoh N, Harada M, Maemondo M, Saijo Y, Dosaka-Akita H, Isobe H, Nukiwa T, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Asahina H, et al. Oncology. 2010;79(5-6):423-9. doi: 10.1159/000326488. Epub 2011 Apr 8. Oncology. 2010. PMID: 21474967 Free article. Clinical Trial.
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Takashina T, Asahina H, Oizumi S, Yamada N, Harada M, Takamura K, Yokouchi H, Harada T, Honjo O, Ogi T, Morikawa N, Kinoshita I, Honda R, Nakano K, Kanazawa K, Amano T, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Takashina T, et al. Int J Clin Oncol. 2018 Dec;23(6):1060-1069. doi: 10.1007/s10147-018-1318-z. Epub 2018 Jul 19. Int J Clin Oncol. 2018. PMID: 30027464 Free article. Clinical Trial.
16 results